14 related articles for article (PubMed ID: 38719543)
1.
Battaglin F; Baca Y; Millstein J; Yang Y; Xiu J; Arai H; Wang J; Ou FS; Innocenti F; Mumenthaler SM; Jayachandran P; Kawanishi N; Lenz A; Soni S; Algaze S; Zhang W; Khoukaz T; Roussos Torres E; Seeber A; Abraham JP; Lou E; Philip PA; Weinberg BA; Shields AF; Goldberg RM; Marshall JL; Venook AP; Korn WM; Lenz HJ
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212126
[TBL] [Abstract][Full Text] [Related]
2. Genes and Race in Colon Cancer.
Stebbing J; Schlechter BL
J Clin Oncol; 2024 Feb; 42(4):369-372. PubMed ID: 38060992
[No Abstract] [Full Text] [Related]
3. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
Innocenti F; Mu W; Qu X; Ou FS; Kabbarah O; Blanke CD; Venook AP; Lenz HJ; Rashid NU
J Clin Oncol; 2024 Feb; 42(4):399-409. PubMed ID: 37992266
[TBL] [Abstract][Full Text] [Related]
4. Pathologic Evaluation of Therapeutic Biomarkers in Colorectal Adenocarcinoma.
Baranov E; Nowak JA
Surg Pathol Clin; 2023 Dec; 16(4):635-650. PubMed ID: 37863556
[TBL] [Abstract][Full Text] [Related]
5. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
6. CCR5 status and metastatic progression in colorectal cancer.
Suarez-Carmona M; Chaorentong P; Kather JN; Rothenheber R; Ahmed A; Berthel A; Heinzelmann A; Moraleda R; Valous NA; Kosaloglu Z; Eurich R; Wolf J; Grauling-Halama S; Hundemer M; Lasitschka F; Klupp F; Kahlert C; Ulrich A; Schneider M; Falk C; Jäger D; Zoernig I; Halama N
Oncoimmunology; 2019; 8(9):e1626193. PubMed ID: 31428524
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
[TBL] [Abstract][Full Text] [Related]
8. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
[TBL] [Abstract][Full Text] [Related]
10. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
Jacobson JM; Saag MS; Thompson MA; Fischl MA; Liporace R; Reichman RC; Redfield RR; Fichtenbaum CJ; Zingman BS; Patel MC; Murga JD; Pemrick SM; D'Ambrosio P; Michael M; Kroger H; Ly H; Rotshteyn Y; Buice R; Morris SA; Stavola JJ; Maddon PJ; Kremer AB; Olson WC
J Infect Dis; 2008 Nov; 198(9):1345-52. PubMed ID: 18771406
[TBL] [Abstract][Full Text] [Related]
11. CCR5 and CCL5 in metastatic colorectal cancer.
Schlechter BL; Stebbing J
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38719543
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
